Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy.

The article discusses a randomized phase-two study which determines whether changes in nuclear factor kappa B (NF-ƘB) activity corresponded with changes in the expression of NF-ƘB target genes. In the said study, the newly diagnosed patients with acute myelogenous leukemia (AML) eligible for standard induction chemotherapy were assigned to choline magnesium trisalicylate (CMT) or no CMT.